Lipella Pharmaceuticals Common Stock Today

LIPO Stock   0.31  0.03  10.71%   

Performance

Weakest

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Lipella Pharmaceuticals is selling at 0.31 as of the 13th of December 2025; that is 10.71 percent up since the beginning of the trading day. The stock's open price was 0.28. Lipella Pharmaceuticals has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 14th of September 2025 and ending today, the 13th of December 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
19th of December 2022
Category
Healthcare
Classification
Health Care
Lipella Pharmaceuticals is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 4.62 M outstanding shares of which 100.09 K shares are now shorted by private and institutional investors with about 3.32 trading days to cover. More on Lipella Pharmaceuticals Common

Moving together with Lipella Stock

  0.86OPTI OptiBiotix Health PlcPairCorr
  0.63ROQ Roquefort Investments PLCPairCorr

Moving against Lipella Stock

  0.89NAUT Nautilus BiotechnologyPairCorr
  0.82600201 Jinyu Bio TechnologyPairCorr
  0.76ESPR Esperion TherapeuticsPairCorr
  0.73PTN Palatin TechnologiesPairCorr
  0.69GILD Gilead SciencesPairCorr
  0.55VIR Vir BiotechnologyPairCorr

Lipella Stock Highlights

Chairman, CoFounderJonathan MBA
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Lipella Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lipella Pharmaceuticals' financial leverage. It provides some insight into what part of Lipella Pharmaceuticals' total assets is financed by creditors.
Liquidity
Lipella Pharmaceuticals Common currently holds 47.6 K in liabilities. Note, when we think about Lipella Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Other Cashflows From Financing Activities

2.98 Million
Lipella Pharmaceuticals Common (LIPO) is traded on NASDAQ Exchange in USA and employs 5 people. Lipella Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.45 M. Lipella Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.62 M outstanding shares of which 100.09 K shares are now shorted by private and institutional investors with about 3.32 trading days to cover. Lipella Pharmaceuticals generates negative cash flow from operations
Check Lipella Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Lipella Pharmaceuticals Common secures 6.52 % of its outstanding shares held by insiders and 1.3 % owned by institutional investors.
Check Lipella Ownership Details

Lipella Stock Institutional Holders

InstituionRecorded OnShares
Tower Research Capital Llc2025-06-30
0.0
Mccormack Advisors International2025-06-30
0.0
Virtu Financial Llc2025-03-31
0.0
Bank Of America Corp2025-06-30
0.0
View Lipella Pharmaceuticals Diagnostics

Lipella Pharmaceuticals Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Lipella Pharmaceuticals market risk premium is the additional return an investor will receive from holding Lipella Pharmaceuticals long position in a well-diversified portfolio.

Lipella Stock Against Markets

Lipella Pharmaceuticals Corporate Executives

Elected by the shareholders, the Lipella Pharmaceuticals' board of directors comprises two types of representatives: Lipella Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipella. The board's role is to monitor Lipella Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lipella Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipella Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael MDChief CoFounderProfile
When determining whether Lipella Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipella Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipella Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipella Pharmaceuticals Common Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.33)
Revenue Per Share
0.216
Quarterly Revenue Growth
(0.36)
Return On Assets
(1.18)
Return On Equity
(2.48)
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.